The antibody market has become a cornerstone of modern biotechnology and pharmaceutical industries, underpinning a vast array of diagnostic and therapeutic applications. Antibodies, which are proteins ...

The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against ...

Cell and gene therapies harbor great hopes for biomedicine. They are becoming increasingly important for diseases that are ...

These antibodies destroy red blood cells faster than your body can make them. Cold autoimmune hemolytic anemia. Also known as cold agglutinin disease (CAD), this is when your body makes specific ...

The lack of funding is expected to set back decades' worth of progress against HIV, according to public health experts.

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

Their work highlights antibody features that could help people design better vaccines for HIV and even autoimmune diseases. "This work gives us a clearer picture of how these antibodies interact ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.